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ABSTRACT Paramyxoviruses,afamilyofRNAenvelopedvirusesthatincludeshumanparainﬂuenzavirustype3(HPIV3),cause
themajorityofchildhoodcroup,bronchiolitis,andpneumoniaworldwide.Infectionstartswithhostcellreceptorbindingand
fusionoftheviralenvelopewiththecellmembraneatthecellsurface.Thefusionprocessrequiresinteractionofthetwoviral
surfaceglycoproteins,thehemagglutinin-neuraminidase(HN)andthefusionprotein(F).Wehavepreviouslyshownthatvi-
ruseswithanHN/FpairthatishighlyfusogenicinmonolayersofimmortalizedcellsduetomutationsinHN’ssecondarysialic
acid binding site are growth impaired in differentiated human airway epithelium (HAE) cultures and in vivo. Here we have
shownthatadaptationofHPIV3togrowthinthelungisdeterminedbyspeciﬁcfeaturesofHNandFthataredifferentfrom
thoserequiredforgrowthinculturedimmortalizedcells.AnHPIV3virusbearingamutatedHN(H552Q),whichisﬁtandfuso-
genicinimmortalizedcellsbutunﬁtforgrowthinthelung,evolvedintoaless-fusogenicbutviablevirusindifferentiatedhu-
manairwayepithelium.StepwiseevolutionledtoaprogressivedecreaseinefﬁciencyoffusionactivationbytheHN/Fpair,with
amutationinFﬁrstdecreasingtheactivationofFbyHNandamutationinHN’ssecondarysialicacidbindingsitedecreasing
fusionactivationfurtherandproducingastablevirus.AdaptationofHPIV3tosuccessfulgrowthinHAEisdeterminedbyspe-
ciﬁcfeaturesofHNandFthatleadtoalesseasilyactivatedfusionmechanism.
IMPORTANCE Humanparainﬂuenzaviruses(HPIVs)areparamyxovirusesthatcausethemajorityofchildhoodcasesofcroup,
bronchiolitis,andpneumoniaworldwide,buttherearecurrentlynovaccinesorantiviralsavailablefortreatment.Enveloped
virusesmustfusetheirmembranewiththetargetcellmembraneinordertoinitiateinfection.Parainﬂuenzavirusfusionpro-
ceedsviaamultistepreactionorchestratedbythetwoglycoproteinsthatmakeupitsfusionmachine.Thereceptor-binding
hemagglutinin-neuraminidase(HN),uponreceptorengagement,activatesthefusionprotein(F)topenetratethetargetcelland
mediateviralentry.Inthisstudy,weshowthattheprecisebalanceoffusionactivationpropertiesofthesetwoglycoproteinsdur-
ingentryiskeyforinfection.Inclinicallyrelevanttissues,virusesevolvetoacquireasetoffusionfeaturesthatprovidekeyclues
aboutrequirementsforinfectioninhumanbeings.
Received 4 May 2012 Accepted 8 May 2012 Published 5 June 2012
Citation Palmer SG, et al. 2012. Adaptation of human parainﬂuenza virus to airway epithelium reveals fusion properties required for growth in host tissue. mBio 3(3):e00137-12.
doi:10.1128/mBio.00137-12.
Editor Diane Grifﬁn, Johns Hopkins University School of Public Health
Copyright © 2012 Palmer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported
License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
Address correspondence to Anne Moscona, anm2047@med.cornell.edu.
H
uman parainﬂuenza virus 3 (HPIV3) is a major cause of pe-
diatric croup, bronchiolitis, and pneumonia worldwide, and
in the United States it accounts for a signiﬁcant share of pediatric
respiratory hospitalizations, as well as a rising number of infec-
tions in immunocompromised patients. There are no vaccines or
treatments against it or any of the other HPIVs (1–4). HPIVs are
enveloped paramyxoviruses, carrying two surface glycoproteins,
the hemagglutinin-neuraminidase (HN) and the fusion (F) pro-
tein. After binding to the host receptor, sialic acid, HN and F
interact to mediate fusion prior to delivery of the viral genome
into the host cell. The correct timing of F activation by HN is
essential for infection: to be effective, triggering of F to its active
state must occur only when F is positioned near the target cell
membrane (5).
The HN protein, which is present as a tetramer composed of
two dimers on the surface of the virus and the infected cell, per-
formsthreeimportantfunctionsduringtheHPIV3virallifecycle.
In addition to receptor binding, the initial step of entry, and F
activation, which promotes the steps of entry after receptor bind-
ing,HNhasthethirdfunctionofreceptorcleavage,performedby
its neuraminidase activity to promote the budding of new viruses
from an infected cell. The communication between the two mol-
eculesthatcomprisetheparamyxovirusfusionmachineisbiolog-
ically relevant, with impact on infection in the natural host. We
have studied HPIV3 virus variants bearing mutations at one of
HN’s sialic acid receptor binding sites, either in the primary re-
ceptorbindingsiteidentiﬁedintheexistingcrystalstructureorin
a secondary sialic acid binding site (site II), present at the dimer
interface and required for activation of F (6–8). Alterations in site
IIatthedimerinterfaceofHPIV3HNinﬂuencegrowth,implicat-
ingHN’ssiteIIinpathogenesis(9).ThevirusHPIV3HNH552Q,
bearing a mutation at HN’s site II, binds its receptor more avidly,
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tensively(6,7),andphysicallyinteractswithFmorestrongly(10).
However, this virus is unﬁt in vivo (cotton rat model) and in hu-
man airway epithelium (HAE), a pseudostratiﬁed, highly differ-
entiated model of unpassaged primary cells that closely resembles
the epithelial tissue of the human respiratory tract (9). This sug-
geststhatanincreaseinFactivationefﬁciencyisadisadvantagein
the natural host. The virus with enhanced F triggering produces
inactive viral particles in HAE, in which the F protein may have
been triggered before contacting target cells (9). These HN-F re-
lationships are physiologically relevant (9): too-active HN-F in-
teractionmayleadtopremature,andthereforeineffective,activa-
tion of the fusion process (5).
To obtain experimental support or proof for this notion, we
turned to the virus and the process of natural selection: in HAE,
which includes a variety of cell types, cilia, and mucus, as in the
human lung (11), the site II-mutated variant HPIV3 HN H552Q
virus adapted for survival by evolving to decrease the ease of trig-
gering of F and the extent of fusion. We have shown here that
infection in lung tissue depends upon a speciﬁc balance of fusion
activation,determinedbyboththeefﬁciencyofHNattriggeringF
and the stability of the pretriggered state of F. Viruses with highly
efﬁcient F-triggering capacity—whether HN triggers F too efﬁ-
cientlyorFistooreadilytriggered—werenotfavoredintheselec-
tion process, likely due to premature triggering of F. The HPIV3
HN H552Q variant virus under the selective pressure of HAE ac-
quired sequential mutations in the F and HN proteins that low-
eredHN-receptorinteractionandloweredFactivation,ultimately
promoting growth in HAE. The ﬁrst mutation emerged in the F
protein, followed by a mutation in HN’s secondary sialic acid
binding site. No reversion to the laboratory wild-type (wt) virus
was identiﬁed. The new HPIV3 variant that emerged during
growth of HPIV3 HN H552Q in HAE carries an HN-F fusion
apparatus with functional properties that are suited to growth in
lung tissue.
RESULTS
Growth of HPIV3 HN H552Q in HAE is ineffective but leads to
emergenceofplaquesizevariantviruses.ThevariantHPIV3HN
H552QinfectedHAEcells,butby3daysitdidnotproduceinfec-
tious progeny virions, yielding only noninfectious viral particles
(9,12).TodeterminewhethertheselectivepressureofHAEwould
yield a virus suited to growth in HAE, HPIV HN H552Q was
growninHAEfor12days.Cultureswereinfectedwith4,000PFU
of either HPIV3 wt or HN H552Q, ﬂuids containing released vi-
ruses were collected each day postinfection, and titers were deter-
mined in cell monolayers (Fig. 1).
Figure 1A outlines the experiment. Infection with HPIV3 wt
(blue line) produced infectious titers throughout the experiment,
with plaque size remaining unchanged after 12 days. In contrast,
infection with HPIV3 HN H552Q (bright red) yielded zero viral
titer up to 3 days after infection. At 5 days after infection, a mixed
population (brown) of medium-plaque (diameter, 0.39 mm) and
small-plaque (diameter, 0.12 mm) viruses was retrieved in repli-
cate experiments, unlike either the large plaques (diameter,
1.08 mm) of the highly fusogenic parental HPIV3 HN H552Q or
plaquesofHPIV3wt(diameter,0.61mm),asshowninFig.1B.By
7 to 9 days after infection, the population contained only small-
plaque viruses, at titers greater than those of HPIV3 wt (data not
shown), and medium-plaque virus did not reappear. This pattern
of emergence of variant viruses consistently reoccurred in each of
the seven times that this experimental protocol was carried out.
ToassessthegrowthinHAEofthemedium-andsmall-plaque
viruses relative to that of parental HPIV3 HN H552Q, samples
were plaque puriﬁed and used to infect HAE. Their growth was
compared to those of the parent and wild-type viruses (Fig. 1C).
As expected, up to 3 days postinfection, HPIV3 HN H552Q
yielded zero titer, while the HPIV3 wt produced 105 PFU/ml. In-
fection with the medium-plaque virus yielded up to 104 PFU/ml
2 days postinfection, followed by emergence of a mixed popula-
tion of medium and small plaques, with only small plaques by
7 days postinfection (data not shown). Infection with the small-
plaquevirusyieldedgrowthupto3logshigherthanthatofHPIV3
wtwithintheﬁrst3daysofHAEinfection,peakingat107PFU/ml.
The HN H552Q variant appears to have undergone sequential
alterations that overcame its growth defect in HAE. The associ-
ated, progressive decrease in plaque size (Fig. 1B) suggests selec-
tion in HAE for viruses with a lower cell fusion capacity.
The high infectious titers attained in HAE by the small-plaque
virusrelativetothoseofthewtvirus,aswellasHPIV3HNH552Q,
might be accounted for by an increase in the number of released
virions (total particles). However, quantiﬁcation by quantitative
real-time PCR (qRT-PCR) of the amount of genome retrieved
from HAE 3 days after infection for the small-plaque virus was
similar to that for wt virus of HPIV3 HN H552Q (Fig. 1D). This
similarity permitted calculation of the amounts of infectious viri-
ons. On average, 60% of the small-plaque virus population was
infectious,asopposedto15%oftheHPIV3wtpopulationand0%
for the HPIV3 HN H552Q variant (Fig. 1E). Thus, while all three
viruses produce particles, the ratio of infectious particles to total
particles is higher in the stable small-plaque virus that emerges
from the HPIV3 HN H552Q parent in HAE.
Viability of emerging variants is associated with mutations
in HN and F envelope glycoproteins. The RNA of the viruses
emergingfromsixdifferentinfectionsofHAEwithHPIV3wt,HN
H552Q,themedium-plaqueviruses,andthesmall-plaqueviruses
was extracted, and the HN and F genes were sequenced (Table 1).
Viruses retrieved from HAE infected with HPIV3 wt retained wt
HN and F sequences. Noninfectious HPIV3 HN H552Q collected
1 day postinfection carried HN with the H552Q mutation and
wild-typeF.Themedium-plaquevirus(theﬁrsttoappear)carried
HN H552Q and F G396D. The small-plaque virus carried the HN
H552Q and F G396D mutations, as well as a Q559R mutation in
HN. Figure 2A shows the HPIV3 HN dimer structure, with
H552Q and Q559 marked; Fig. 2B shows the homology model of
the HPIV3 F protein prefusion structure, and the HPIV3 F post-
fusion structure, with G396 marked. The Q559R HN mutation is
located in the secondary sialic acid binding site that is present at
the dimer interface and has been implicated in activation of F (7,
13).
Evolution towards slower HN-F triggering and fusion. The
failureofthehighlyfusogenicHPIV3HNH552Qvirustoproduce
active virions in HAE infection could be due to the premature
triggering of the F protein in the progeny virions, leading to inac-
tivation of the virions (9). In this case, positive selection in HAE
should favor mutations that overcome this tendency to prema-
turely trigger F. A quantitative fusion assay was used to evaluate
thefusionpromotioncapacityofeachHN-Fpair(7,13,32).293T
cells coexpressing F wt or F G396D with HN H552Q or HN
H552Q,Q559R were overlaid with receptor-bearing cells at 37°C
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(Fig. 1B), fusion is reduced if F G396D (instead of wt F) is paired
with HN H552Q. Fusion decreased by 32% when wt F is replaced
withFG396D,indicatingthatthemutationG396Dproducedless
fusioninthepresenceofthesameH552QHN(Fig.3A).Withthe
second HN mutation (H552Q Q559R), the fusion capacity de-
FIG1 HAEinfectionwithHPIV3HNH552Q:emergenceofvariants.(A)TimelineofviralgrowthafterinfectionofHAEwithwtHPIV3(blue)andHPIV3HN
H552Q(red).(B)PlaquediameterinCV1cells16to18hafterinfectionwiththeindicatedvirusretrievedfromHAE(n20pervirusfrom3experiments).(C)
Titers of viruses grown in HAE: wt HPIV3 (blue), HPIV3 HN H552Q (red), or HPIV3 “small plaques” (brown). Data points are means (SD) of triplicate
measurementsandarerepresentativeofatleast5experiments.(D)Quantitationofviralgenomereleased3dayspost-HAEinfection(determinedbyqRT-PCR).
Data points are means (SD) of triplicate experiments. (E) Percentage of infectious virions (out of total particles) retrieved from infection of HAE.
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decreased the efﬁciency of the HN-F fusion pair.
Speciﬁc HN-F-triggering efﬁciency was assessed using a
fusion-triggering assay to determine the temperature of F activa-
tion for each HN-F pair. Cells coexpressing the indicated HN and
F pair (Fig. 3B) were allowed to bind erythrocytes (RBCs) at 4°C.
The cells were then washed to remove unbound RBCs and trans-
ferred to fresh medium at 4, 15, 22, 30, or 37°C for 1 h, to allow F
activation. The amount of target RBCs that (i) were released into
the medium by HN’s innate neuraminidase activity (dotted line),
(ii) were bound but had not fused (dashed lines), or (iii) had
undergone fusion (solid lines) was determined. The temperature
of F activation (deﬁned as the temperature for 50% RBC fusion)
increased from 12°C for HN H552Q with F wt to 29°C for HN
H552Q with F G396D (medium plaques), indicating that the F
mutantrequiresmoreheatenergytobeactivatedthandoesFwtin
the presence of the same HN (Fig. 3B). The virus yielding stable
and infectious small plaques, bearing HN H552Q,Q559R and F
G396D, had the highest temperature requirement (37°C) for F
activation, achieving only 20% fusion at 37°C. The ﬁnal extent of
fusion accomplished by this HN/F pair is also affected by the sig-
niﬁcant amount of release of RBCs from the expressing cell sur-
faces; this issue will be further addressed below (see Fig. 5C).
The mutation G396D confers slower activation kinetics of
the F protein. The effect of the G396D mutation in F could result
from less-efﬁcient triggering or from less-effective fusion promo-
tion after triggering. To distinguish between these two possibili-
ties,heatactivationofwtFandmutantFG396Dintheabsenceof
HN was carried out. Hemagglutinin (HA) can be used to bind to
receptor-bearing cells that are targets for HPIV3 F-mediated fu-
sion;sinceinﬂuenzavirusHAandHPIV3Fdonotinteractonthe
cell surface and HA does not trigger F to mediate fusion (10), HA
serves simply to cause the cells to adhere. Cells were transfected
with inﬂuenza virus HA with either wt F or mutant F G396D, the
cells were incubated at 45°C to activate F (14, 15), and fusion was
measuredovertime(Fig.4).At30min,FG396Dshowedapprox-
imately 18% less fusion than F wt. By 60 min there was no signif-
icant difference in the fusion between F wt and F G396D, indicat-
ing that F G396D was less efﬁcient at initial activation but once
activated was fully fusion competent.
Mutations acquired in HN’s secondary sialic acid binding
site(“siteII”)loweravidity.TodissecttheroleoftheHNQ559R
mutation in the secondary sialic acid binding site, HNs bearing
bothH552QandQ559Rwerecomparedwitheachsinglymutated
HN and wt HN for receptor avidity, neuraminidase, and
F-triggeringproperties.Tomeasurereceptorbindingavidity,cells
transientlyexpressingeitherofthefourHNswerepretreatedwith
neuraminidase to remove receptors on the expressing cells’ sur-
facesandeliminatepotentialinteractionsbetweenHNandrecep-
tor molecules on the HN-expressing cell surface (7). Aliquots of
RBCs with graded receptor depletion were then used to quantify
RBC binding to the HNs; HN molecules with higher avidity bind
RBCs that have lower receptor density (higher depletion). As ex-
pected,HNH552QshowedhigheraviditythanHNwt(50%bind-
ing to RBCs treated with 54 mU of neuraminidase, compared to
50% binding to RBCs treated with 44 mU neuraminidase)
(Fig. 5A). For HN H552Q,Q559R, avidity is markedly reduced
(50% binding at 19 mU neuraminidase). This decrease can be
accountedforbytheQ559Rmutation,whichsingly(HNQ559R)
showed 50% binding at 17 mU of neuraminidase. The strikingly
reduced avidity conferred by Q559R points to the role of the sec-
ondary sialic acid binding site in receptor avidity.
The Q559R mutation also impacted HN’s neuraminidase ac-
tivity, known to reside in site I. Neuraminidase activity of the
doubly mutated HN H552Q,Q559R was approximately 80% of
TABLE 1 Mutations acquired in HN and F glycoproteins of HPIV3
variants
HPIV3 variant HN mutation(s) F mutation
HN H552Q H552Q None
Medium-plaque virus H552Q G396D
Small-plaque virus H552Q, Q559R G396D
FIG2 Molecularstructureofwild-typeandmutantHNandF.(A)HNdimer
structure (PDB IV2I), with the monomers colored gray and cyan. The loca-
tions of the H552Q and Q559R mutations at the dimer interface are high-
lighted by showing residues H552 and Q559 as sticks and marked with aster-
isks. The structure was subjected to 20 ns of MD simulation. (B) Crystal
structure of the postfusion HPIV3 F protein (right) and a homology model of
theprefusionprotein,basedonPIV5F(left).ThethreechainsofFarecolored
green, cyan, or magenta. The G396 residues are represented as yellow spheres.
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anallostericeffectonsiteI,butthisremainstobeexploredmech-
anistically.Sinceboththebindingandneuraminidaseactivitiesof
HN were affected by the Q559R mutation, we hypothesized that
thedurationofreceptorengagementmaybeshorterforthesmall-
plaque virus’ HN than for parental HN H552Q. To address this
question,thetimecourseofeachHN’sbindingandreleasingsialic
acid receptors was determined at 37°C. Cells expressing HN WT,
HN H552Q, HN H552Q,Q559R, or HN Q559R were incubated
with 1% RBC suspensions for 30 min at 4°C, rinsed to remove
unbound RBCs, and transferred to 37°C. At the indicated time
points (Fig. 5B), the released and bound RBCs were collected and
quantiﬁed. Within 15 min of incubation at 37°C, approximately
44%and47%ofRBCswerereleasedfromHNH552Q,Q559Rand
HN Q559R, respectively, compared to only 13% for HN wt and
0.7% for HN H552Q. This faster receptor detachment from HN
H552Q,Q559RandHNQ559Rreﬂectsthelowerratioofreceptor
avidity to neuraminidase activity for these variant HNs than for
parental HN H552Q.
MutationsacquiredinHN’ssiteIIimpairHN’sF-triggering
ability.ToaddresstheeffectofQ559RonHN’sFactivationprop-
erty, the fusion-triggering assay was carried out with HN wt, HN
H552Q,Q559R, or HN Q559R coexpressed with F wt. Again the
FIG3 Cell fusion promoted by parental and mutant glycoproteins. (A) Cell-cell fusion mediated by the indicated HN-F pairs was quantitated after 3 h at 37°C
usingabeta-galactosidasecomplementationassay.ThebarsrepresentmeansSDofdatafromatleast3experiments.(B)293Tcellscoexpressingtheindicated
HN-F pair were allowed to bind RBCs at 4°C and then transferred to 4, 15, 22, 30, or 37°C for 1 h. Released, bound, and fused RBCs were quantiﬁed. The values
are means (SD) of results from three experiments.
FIG4 Activation kinetics of F wt and F G396D in the absence of HN at 45°C.
293T cells transiently expressing inﬂuenza virus HA and either F wt or F
G396D were overlaid with RBCs at 45°C for 60 min. The percent RBCs fused
(y axis) over time (x axis) was quantiﬁed. The values are means (SD) of
results from three experiments.
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at which there is 50% RBC fusion. HN wt required a temperature
of 18°C to achieve 50% binding or fusion (Fig. 5C). HN H552Q,
the most efﬁcient at F triggering, required only 12°C (Fig. 3B).
IntroductionofQ559RintotheparentalHNH552Qincreasedthe
activation temperature to 31°C, while singly mutated HN Q559R
FIG 5 Effects of HN mutation on avidity, neuraminidase, receptor release, and F activation. (A) A panel of RBCs with different degrees of receptor depletion
wasusedtoquantifyHADon293TcellmonolayersexpressingtheindicatedHNs.Thevaluesaremeans(SD)ofresultsfromthreeexperiments.(B)293Tcells
transientlyexpressingtheindicatedHNwereallowedtobindRBCsat4°Cfor30minatpH5andthentransferredto37°C.PercentRBCsreleasedat0,5,10,15,
30, and 60 min were determined (y axis). Values are means (SD) of results from triplicate wells. (C) 293T cells coexpressing the indicated HN-F pair were
allowed to bind RBCs at 4°C and then transferred to 4, 15, 22, 30, or 37°C for 1 h. RBCs released, bound, and fused were quantiﬁed. Values are means (SD) of
results from three experiments.
TABLE 2 Characteristics of variant HPIV3 HN and F proteins
Protein
Receptor avidity
(mU for 50%
RBC binding)
Neuraminidase
level
(% of HN
wt level)
Release
(% RBC released
in 15 min at
pH 5)
Temp of F activation (°C)
F wt F G396D
HN wt 44 100 13 18 37
HN H552Q 54 79.5 0.7 12 29
HN H552Q,Q559R 19 62.2 44 31 37
HN Q559R 17 34.4 47 37 37
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Q559R mutation confers a decrease in the efﬁciency of HN’s
F-triggering property.
It is conceivable that the F activation temperatures of HN
H552Q,Q559R and HN Q559R might have been obscured by the
signiﬁcant release of RBCs during the fusion-triggering assay. To
addressthisissue,weremovedtheneuraminidaseactivityofthese
HNs in order to evaluate simply the inherent F-triggering ability
oftheHNs.ThemutationD216R,whichabolishesneuraminidase
activity without affecting binding or F activation (13), was intro-
duced into HN H552Q,Q559R and HN Q559R. HN carrying the
D216R mutation is irreversibly receptor engaged. The HN
D216R,H552Q,Q559R construct did not produce a functional
protein on the cell surface, but HN D216R,Q559R was expressed
at levels comparable to those for all other HNs (data not shown).
Using HN D216R,Q559R in the presence of F wt, the fusion-
triggeringassayrevealedthatevenwithoutreleaseofRBCsduring
the fusion assay, the temperature of activation for HN
D216R,Q559R was still 28°C (Fig. 5C). This suggested that HN
Q559R was inherently less efﬁcient at activating F relative to HN
wt and HN H552Q, a result not explained simply by release of
receptor-bearing cells prior to F activation.
Coevolution of HN and F in HAE identiﬁes key characteris-
tics required for HPIV3 growth in the lung. To achieve optimal
growth characteristics in host tissue, the large-plaque HPIV3 HN
H552Q virus underwent evolution to reduce the efﬁciency of its
fusion machinery in several ways: by decreasing F’s susceptibility
to activation, by decreasing HN’s receptor avidity, by decreasing
HN’s neuraminidase, and by decreasing HN’s fusion-triggering
capacity. The combination of characteristics led to diminished
HN-F activation. Table 2 summarizes the individual characteris-
tics of each protein in the series. The parent HPIV3 HN H552Q
ﬁrst acquired a mutation in F that impacted F’s ability to be acti-
vated, but this mutation alone was insufﬁcient for generating a
stable virus. The introduction of Q559R into HN’s site II resulted
in a decrease in avidity, neuraminidase, and HN’s F-triggering
functions, producing a virus that is viable in the lung tissue.
DISCUSSION
Infection by HPIV3 in lung is an ongoing positive selection pro-
cess in which the strength of binding to host cells, fusion activa-
tion, and receptor cleavage ﬂuctuate until a stable balance is
achieved. Our previous studies have shown that avid binding of
HNtothehostcellreceptor,pairedwithefﬁcientfusionactivation
by HN, was suited for infection and growth in monolayer culture
but proved to be counterproductive in cotton rats and HAE (9).
The studies reported here on the evolution of the virus in natural
tissue,achievedthroughexperimentsthatpermittheHN/Ffusion
machinery to adapt in the natural host, explain the differences in
outcomes in terms of speciﬁc HN-F activities over time.
A key factor for viral infection in the host is an HN that does
notprematurelyactivateFbeforeviralentry.Severalviralproper-
ties contribute to this effect. In the lung, HPIV3 bearing an HN
with lower avidity may be superior to one with a more avid HN
because the resulting requirement for higher activation energy
protects F from activation, delaying the triggering of F until the
conditions are right for fusion. We have suggested (5, 9) that the
correcttimingofFactivationisessentialforviralentryandspread
andthattriggeringshouldoccuronlywhenFisinproximitytothe
target cell membrane. HPIV3 HN H552Q produced noninfec-
tious particles after primary infection of HAE (9), and we now
have found that exposure to the selective pressure of growth in
HAE favored the emergence of a new viral variant with slower
fusion kinetics. It is possible that the generous availability of re-
ceptors in the lung could be the factor in HAE that caused HPIV3
HN H552Q viruses to be noninfectious after the primary infec-
tion. HN H552Q, avid for receptor binding and efﬁcient at F ac-
tivation, would result in these viruses binding to sialic acid-
containingmoietiesinthelung,leadingtoprematureactivationof
F. The virus that emerged under the selective pressure in HAE
(HPIV3 HN H552Q,Q559R F G396D) carries an HN with lower
avidityforreceptorbindingandless-efﬁcientactivationofF.This
variant grows even better than our lab-adapted wt HPIV3 in the
HAE. These slow fusion machinery characteristics may also be
shared with HPIV3 clinical isolates; an analysis is ongoing. Spe-
ciﬁcfusionkineticsmaybeakeyfactorinlong-termvirussurvival
and growth in vivo.
The appearance and survival of the mutations in HN and F
over time suggest several key characteristics of successful HN-F
interactions. In host tissue, from a highly avid and fusogenic
HPIV3 carrying HN H552Q, a new and unstable variant was pos-
itively selected with a mutated fusion protein that was less fuso-
genic than its predecessor. This unstable virus then acquired a
second mutation in HN’s secondary sialic acid binding site—
Q559R—to form a stable and poorly fusogenic virus, which grew
better in HAE than the HPIV3 wt virus that has been propagated
inthelaboratory.Theseﬁndingssuggestthattheemergenceofthe
less-fusogenicFproteinmutantrequiredchangesinHN’ssiteIIto
achieveastablevirus.Conversely,themutationsthatwereadvan-
tageousforgrowthinnaturaltissueledtopoorgrowthinimmor-
talized cells; infection of CV1 cells with HPIV3 HN
H552Q,Q559R/F G396D led to the acquisition of new mutations
in the glycoproteins and a change in plaque size and morphology
(data not shown).
The H552 and Q559 residues are located at the HN dimer
interface,nearthesecondactivesiteinthepublishedX-raycrystal
structure of HN (PDB 1V2I) (16) (Fig. 2A). The introduction of
Q559R was the ﬁnal step in the evolution from a virus unﬁt for
growthinlungtoastableHPIV3variantthatishighlyinfectiousin
HAE.WhiletheH552Qmutationconfershigheravidityforrecep-
tors and increased F triggering relative to results for HN wt, the
introduction of Q559R into the HN protein has the opposite ef-
fect. Q559R decreases HN’s avidity for receptors as well as its
ability to activate the F protein. Note that the HN surface expres-
sion levels do not differ between wt HN and mutants, including
HN containing the Q559R mutation (Table 3). Using the pub-
lished HN structure (above), the H552 residue was mutated to Q
in silico. The mutation did not signiﬁcantly alter the dimer inter-
face or the local protein conformation. Based on this modeling
TABLE 3 Flow cytometric analysis of HN cell surface expression by
FACS analysis with anti-HN monoclonal antibody
Protein
No. of cell surface
HN molecules/cella
HN wt 91,200  24,617
HN H552Q 90,041  19,838
HN H552Q,Q559R 93,263  14,342
HN Q559R 96,878  12,439
a Data are representative of results from four experiments (averages  SE).
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seem to disrupt and might in fact strengthen the interaction and
participates in intermolecular hydrogen binding; this could ac-
count for our recent biochemical data showing that H552Q alters
dimerization of HN (10).
The second mutation at this site, Q559R, might disrupt the
dimer observed in the crystal structure. The arginines facing each
other, in addition to not ﬁtting into the tight space at the dimer
interface, could create charge repulsion, possibly disrupting the
dimer. However, generating this mutation in silico is not possible
becausethedimerinterfaceofthecurrentlyavailablecrystalstruc-
ture of HN (16) does not permit this mutation. Additional struc-
tural analysis will explore the effects of this mutation on HN.
TheresiduemutatedintheFprotein,glycine396,islocatedon
a long loop of F’s domain II, which is surface exposed both in the
postfusioncrystalstructure(PDB1ZTM)(17)andinahomology
model of the prefusion structure (model based on the parainﬂu-
enza virus 5 [PIV5] F protein, PDB 2B9B) (18) (Fig. 2B). The
G396D position is accessible and remains in the same structural
location in the pre- and postfusion conformations of F. The mu-
tationconfersslowertriggeringkineticsontheprotein,indicating
thatthisdomainisinvolvedinthetriggeringmechanism.Whilein
our study the mutation in F emerged to permit growth in lung
tissue, several experiments using site-directed mutagenesis in
otherparamyxoviruseshaveshownthatmutationsinthisdomain
of F can modulate F activation, most likely by stabilizing the pre-
fusion state (19–21). Of note, this residue is the same location on
F that was targeted by the effective prophylactic monoclonal an-
tibody for respiratory syncytial virus, supporting the notion that
this location is a key functional region that is preserved between
paramyxovirus F proteins (22, 23).
The progressive evolution from the parental HPIV3 HN
H552Q to HPIV3 HN H552Q,Q559R/F G396D, from larger to
smaller plaques and to decreased F triggering, highlights the dis-
advantageoftheparentalvirus’fusionmachinery.TheHN-Fma-
chineryofHPIV3HNH552Q,toadapttothelungtissue,evolved
to decrease its F activation capacity ﬁrst, to grow in HAE, and a
second mutation in HN’s second sialic acid binding site, decreas-
ingavidityandHN’sFactivation,conferredoptimalgrowthinthe
airway cultures. The results support the role of HN’s sialic acid
binding site II in controlling F activation and underscore the no-
tionthattimelyFactivationisrequiredforinfectioninhosttissue.
The HN-F pair of the HAE ﬁt virus requires more energy to initi-
atefusion.Indistinctionfromthefeaturesthatconferfusogenicity
in monolayer cultures, a virus carrying an HN with low receptor
avidity, a high rate of release from the receptor, and decreased
efﬁciencyofactivatingtheFproteinandwithreducedfusionisﬁt
for growth in the natural host.
ThemechanismsunderlyingHN-Factivityofferopportunities
forsubvertingtheviralfusionprocess.Apartfrominhibitingviral
entry, it may be possible to force viral evolution towards develop-
ing HN host receptor binding that is strong enough to prema-
turely activate F and circumvent fusion. Recently, we identiﬁed
compounds that stimulate HPIV3 HN to trigger F prematurely,
before the virus contacts the target cell membrane, and thereby
inactivateinfectivityinHAE(5).Suchcompoundsareofpotential
signiﬁcance as antiparamyxovirus therapies and should be highly
unlikely to elicit resistance mutations. Mutants arising under the
selective pressure of premature-triggering compounds would
have fusion machineries that are too impaired for viability and
would thus be less ﬁt and transmissible than the parent virus.
Virionsharboringmutationsintheirfusionmachinerythatwould
makethemresistanttoprematurelyactivatingcompoundswould
therefore be likely to be unresponsive in physiological situations,
rendering them less ﬁt to infect and cause disease. Characterizing
molecular attributes of HN and F as well as the timing, kinetics,
and interaction between HN and F as a complex in lung tissue
allows us to consider the HN-F fusion machinery with its various
componentsinbalance,asabiologicalcomplex,tunedforsurvival
in the host.
MATERIALS AND METHODS
Humanairwayepithelialcultures.TheEpiAirwayAIR-100system(Mat-
Tek Corporation) consists of normal, human-derived tracheobronchial
epithelial cells that have been cultured to form a pseudostratiﬁed, highly
differentiated mucociliary epithelium. Upon receipt from the manufac-
turer, HAE cultures were handled as previously described (9, 12).
Monolayercells.CV-1(Africangreenmonkeykidney)and293T(hu-
man kidney epithelial) cells were grown in Dulbecco’s modiﬁed Eagle’s
medium(Cellgro;Mediatech)supplementedwith10%fetalbovineserum
and antibiotics at 37°C in 5% CO2.
Viruses. Titers of HPIV3 virus stocks were assessed by a plaque assay
(9, 12). Supernatant ﬂuids collected from HAE were used to infect CV-1
cells.Isolatedplaqueswereenclosedina1-mm-diameterplasticcylinder,
and trypsin was added to disrupt the plaque. Complete medium (100 l)
wasthenadded,andthemixturewascollected.Thisﬂuidwasthenusedto
infect HAE recurrently to ensure that the plaque retained its morphology
over 2 to 3 passages for preparation of viral stocks.
RNAisolationandsequenceanalysisofHNandFgenes.TotalRNA
was isolated from CV1 cells infected with plaque-puriﬁed virus or super-
natantﬂuidscollectedfromHAEortheHAEculturesthemselves,infected
with 4,000 PFU of HPIV3 WT or the variant viruses. RNA isolation and
sequencing were performed as previously described, and sequence analy-
sis was carried out on the DNA products of three separate isolations and
performed twice on all samples to conﬁrm sequence alterations (24, 25).
qRT-PCR. To measure the amount of viral genome released, 30 lo f
ﬂuid containing released virus was processed for RNA extraction, and
then the genome was quantiﬁed using the real-time one-step qRT-PCR
pathogendetectionkitspeciﬁcforHPIV3(PrimerDesign)aspertheman-
ufacturer’s instructions.
ModelingofHNandFandmoleculardynamicssimulation.Formo-
lecular dynamics (MD) simulation, the wt or H552Q mutant HN was
solvatedinawaterboxextending10Åinalldirectionsbeyondtheedgeof
the protein, using the TIP3P water model z (26, 27). The system was
neutralized with a 150 mM concentration of sodium/chloride ions and
consisted of a total of 66,000 atoms. Mutagenesis and system preparation
was performed with the VMD software program (28). MD calculations
were performed with the NAMD program (29) using the CHARMM27
force ﬁeld. The systems were energy minimized with 10,000 steps of con-
jugate gradient energy minimization, followed by gradual heating from 0
to 310 K in 30 ps, and then maintained at constant temperature and
pressure (1.01325  105 Pa). The simulations were carried out with peri-
odicboxconditions,witha2-fstimestep,auniformdielectricconstantof
1,a1to4scalingvalueof1.0,acutoffofnonbondedforceswithaswitch-
ing function starting at 10 Å and reaching 0 at 12 Å, particle mesh Ewald
(PME) with a tolerance of 106, and all bonds involving hydrogens con-
strainedwiththeSHAKEalgorithm.Aproductionrunwasperformedfor
20 ns, and the trajectories were analyzed with VMD.
The structure of the prefusion F protein from HPIV3 was homology
modeled using the HHpred server (http://toolkit.tuebingen.mpg.de
/hhpred#) and the parainﬂuenza virus 5 (PIV5) structure as the template
(18).
Measuring plaque size. Plaque diameter was measured at a magniﬁ-
cationof15underazoomstereomicroscopeequippedwithamicrome-
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plaque areas with standard deviations.
HN and F constructs and transient expression. Cloned HPIV3 HN
variant cDNAs were digested with EcoRI and BamHI and ligated into a
digested pEGFP-C3 vector (BD Biosciences/Clontech). Cloned HPIV3 F
cDNAs were digested with XhoI and BamHI and ligated into digested
pCAGGSmammalianexpressionvectors.Positiveclonesweresequenced
to verify the mutations and to ensure that no additional alterations had
been introduced. Transfections were performed according to the Lipo-
fectaminePlusorLipofectamine2000manufacturer’sprotocols(Invitro-
gen).
Assayofneuraminidaseactivity.Monolayersof293Tcellstransiently
expressing WT or mutant HNs were washed once with phosphate-
bufferedsaline(PBS)andthenincubatedfor10minin5mMEDTAin1
PBS put in pH 5.0 CO2-independent medium (Gibco). Cells (150,000)
were transferred to 96-well plates and incubated at 37°C for 10 min. 2=-
(4-Methylumbelliferyl)-a-d-N-acetylneuraminic acid sodium salt (MUN
ANA) (20 mM; Toronto Research Chemical) was added at 1:1 (vol/vol)
for a ﬁnal concentration of 10 mM MUNANA. A kinetic reading at 37°C
was done using a SpectraMax M5 enzyme-linked immunosorbent assay
(ELISA) reader every 2 min for 1 h.
Useofreceptor-depletedRBCstoassessHNreceptor-bindingavid-
ity. Human RBCs were obtained from healthy donors as previously de-
scribed(24).PartialreceptordepletionofRBCswascarriedout,andRBCs
which were partially depleted of their surface sialic acid receptors were
used to determine the relative receptor binding avidities of variant HN
molecules as described previously (7, 13).
Assays for F activation, receptor retention, and receptor release.
Monolayers of 293T cells transiently expressing F wt or mutant or HN wt
or mutant were washed three times and incubated with 1% RBC suspen-
sionsatpH7.3for30minat4°C.AfterrinsingtoremoveunboundRBCs,
the plates were transferred to 4, 15, 22, 30, or 37°C for 1 h. After this
incubation, RBCs that were released to the medium, remained bound, or
hadundergonemembranefusionwerequantiﬁedasdescribedpreviously
(7, 13).
-Galactosidase complementation-based fusion assay. The
-galactosidase complementation-based fusion assay was performed as
previously described (7, 13, 32).
Cell surface expression assay. Monolayers of 293T cells were trans-
fected for transient expression of HN or F constructs. Cells were washed
twice in PBS and then incubated with an anti-HPIV3 HN monoclonal
antibody supplied by Judy Beeler in 3% bovine serum albumin (BSA),
0.1%sodiumazideinPBSfor1h.SampleswerethenwashedtwiceinPBS
and incubated with 1:100 anti-mouse IgG (HL) R-phycoerythrin con-
jugate(CaltagLaboratories).Toquantifytheamountsofcellsurfacepro-
teins in each sample, an indirect immunoﬂuorescence assay was used,
wherebeadsfromtheQiﬁkitkit(Dako)werestainedsimultaneouslywith
samples according to manufacturer’s instructions, with the same second-
ary antibody. Cell surface expression of all samples and beads was per-
formed with ﬂuorescence-activated cell sorting (FACS) (FACSCalibur;
Becton, Dickinson) (10, 30, 31).
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